Pegylated Recombinant Human Granulocyte Colony-stimulating Factor
- Generic Name
- Pegylated Recombinant Human Granulocyte Colony-stimulating Factor
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
⑴非髓性恶性肿瘤患者在接受会发生有临床意义发热性中性粒细胞减少的抑制骨髓的抗肿瘤药治疗时，使用本品可降低发热性中性粒细胞减少引起的感染发生率。
⑵本品不用于造血干细胞移植的外周血祖细胞的动员。
- Associated Conditions
- -
- Associated Therapies
- -
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Wei Zhao
- Target Recruit Count
- 1500
- Registration Number
- NCT03844360
- Locations
- 🇨🇳
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath